Announcement PDF RNS Number : 2516N N4 Pharma PLC 18 May 2020 18 May 2020 N4 Pharma plc ("N4 Pharma", the "Company" or the "Group") Grant of Options N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the Company has today granted 1,434,286 options (the "Options") over ordinary shares of 0.4 pence in the Company ("Ordinary Shares") to certain Directors of the Company. These Options have been granted pursuant to the Company's Unapproved Share Option Scheme, as follows: Director David Templeton Executive Director Luke Cairns Non-Executive Director Number of Options granted Existing options over Ordinary Shares held Total Options over Ordinary Shares held following grant 717,143 717,143 1,434,286 717,143 1,392,445 2,109,588 The Options have an exercise price of 4.8 pence per Option, being the closing midmarket price of an Ordinary Share on 15 May 2020, the business day prior to the grant. The Options can be exercised from three years from the grant date and up to the tenth anniversary of the grant date, provided that the individual remains an employee of the Company. Following the grant of the Options, the Company has options in issue over a total of 8,396,513 Ordinary Shares, representing 8.28 per cent. of the Company's current issued share capital, or 5.52 per cent. of the Company's issued share capital as enlarged by the placing announced on 13 May 2020. The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below. Enquiries: N4 Pharma Plc Nigel Theobald, CEO Via Scott PR Allenby Capital Limited James Reeve/Asha Chotai Scott PR Georgia Smith Tel: +44(0)203 328 5656 Tel: +44(0)1477 539 539 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 a) 2 a) b) 3 a) b) 4 a) Details of the person discharging managerial responsibilities / person closely associated Name David Templeton Reason for the notification Position/status Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code (ISIN) for N4 Pharma plc ordinary shares: Identification code GB00BYW8QM32 b) Nature of the transaction c) Price(s) and volume(s) Issue of options over ordinary shares of 0.4p each Price(s) Volume(s) 4.8p exercise price 717,143 d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction n/a 18 May 2020 Outside a trading venue Details of the person discharging managerial responsibilities / person closely associated Name Luke Cairns Reason for the notification Position/status Non-Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code (ISIN) for N4 Pharma plc Identification code ordinary shares: GB00BYW8QM32 b) Nature of the transaction c) Price(s) and volume(s) d) e) Aggregated information - Aggregated volume - Price Date of the transaction Issue of options over ordinary shares of 0.4p each Price(s) Volume(s) 4.8p exercise price 717,143 n/a 18 May 2020 f) Place of the transaction Outside a trading venue This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END DSHAPMATMTTBBMM